The illusion and cost of drug rebates
By Peter J. Pitts
President Trump and every declared candidate for the presidency want to lower drug costs. And — surprise — it’s the president who has made a bold move towards a workable free-market solution.
His new proposal cracks down on the price-gouging practices of middlemen in the drug supply chain — prescription benefit managers, the mega-corporations that insurers employ to administer their drug benefits.
The administration’s new proposal impacts Medicare Part D, the federal prescription drug benefit for seniors and those living with disabilities. Beneficiaries can expect more money in their pockets as a result of the proposed rule. Kudos to the president and HHS Secretary Azar for putting patients first.
The Trump plan imposes new restrictions on how PBMs share rebates and discounts in the Part D program. Currently, insurers hire PBMs to negotiate with drug manufacturers. PBMs are able to secure big discounts, usually through rebates, by promising to include specific medicines on preferred insurer formularies.
These rebates aren’t pocket change. By one estimate, the average rebate knocks off nearly 40 percent of a brand name drug’s list price. That’s billions of dollars annually.
In theory, these savings should flow down to insurers and beneficiaries and result in lower out-of-pocket pharmacy costs. But that isn’t how it’s working.
The current system encourages PBMs to favor medicines that carry higher rebates rather than lower list-priced drugs. As a result, patients do not directly benefit from significant price negotiations in the market today.
A recently leaked contract with the nation’ largest PBM, Express Scripts, offers some insight into how PBMs operate.
For starters, PBMs exploit the definition of “rebate” to their financial favor. Rather than categorizing all discounts as rebates, PBMs deduct “administrative” and “service” fees from the discounts they receive. They also slap drug manufacturers with “inflation payments” to account for annual price increases. These tactics hide the true value of manufacturer discounts.
PBMs have been wildly successful with these tactics. The nation’s three largest PBMs, who together control three-quarters of the market, earned a handsome $10 billion in profits in 2015.
President Trump is right to target America’s greedy intermediaries.
Should his plan take effect, PBMs will no longer receive rebates for prescription drugs in the Part D program. Most importantly, the pharmaceutical industry would be encouraged and empowered to pass rebate dollars to patients instead.
Patients will save big. By one estimate, if just one-third of the total discounts PBMs negotiate for Part D were passed on to patients at the pharmacy counter, Medicare beneficiaries would have an extra $20 billion in their bank accounts over the next ten years.
President Trump’s proposal is a great step in putting patients first. His administration deserves praise for this bold move.
Peter J. Pitts, a former FDA associate commissioner, is president of the Center for Medicine in the Public Interest.
The viewpoints expressed above are those of the author and do not necessarily reflect those of The Independent.
How to submit an article, guest opinion piece, or letter to the editor to The Independent
Do you have something to say? Want your voice to be heard by thousands of readers? Send The Independent your letter to the editor or guest opinion piece. All submissions will be considered for publication by our editorial staff. If your letter or editorial is accepted, it will run on suindependent.com, and we’ll promote it through all of our social media channels. We may even decide to include it in our monthly print edition. Just follow our simple submission guidelines and make your voice heard:
—Submissions should be between 300 and 1,500 words.
—Submissions must be sent to editor@infowest.com as a .doc, .docx, .txt, or .rtf file.
—The subject line of the email containing your submission should read “Letter to the editor.”
—Attach your name to both the email and the document file (we don’t run anonymous letters).
—If you have a photo or image you’d like us to use and it’s in .jpg format, at least 1200 X 754 pixels large, and your intellectual property (you own the copyright), feel free to attach it as well, though we reserve the right to choose a different image.
—If you are on Twitter and would like a shout-out when your piece or letter is published, include that in your correspondence and we’ll give you a mention at the time of publication.
